## DVA: DaVita Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.09 indicates fundamental undervaluation. Quality metrics strong (ROE 62%). Caution: momentum weakening (-2.7% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($112.43)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### Analyst Activity

**Target Signal:** BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-03 | TD Cowen | $133 | $154 | -14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-03 | TD Cowen | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($54.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 69.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Berkshire Hathaway, : 45.6% (-4.8%)
- Vanguard Group Inc: 6.0% (-10.9%)
- Blackrock Inc.: 5.1% (-13.1%)
- State Street Corpora: 2.6% (-12.4%)
- Invesco Ltd.: 2.4% (+2.0%)

### Key Risks

1. Heavy insider selling: $55M sold (3 transactions in 90 days).
2. High short interest (21.1%, 7.3 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 13.7% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.09 suggests fair value with growth premium. Forward P/E 9.3x attractive for 19% earnings growth. Quality metrics strong (ROE 62%). Analyst sentiment negative (1 target cuts vs 0 raises). Insider selling cluster ($55.0M in 90 days), potential headwind. Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $8.1B |
| Beta | 0.99 |
| 52W Range | $113.12 - $179.60 |
| Short Interest | 21.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.09 |
| Forward P/E | 9.3 |
| Current P/E | 11.1 |
| YoY Growth | 19.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -0.5% to -3.2% (-2.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.2pp (needs >4.0% for momentum thesis). Underperforming sector by 3.0pp, stock-specific weakness. Below SMA200 (0.86x), long-term trend not supportive. RSI neutral at 42. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.25% (CS: 20) | Weak |
| RSI_14 | 41.9 | Neutral |
| MACD Histogram | 0.30 | Bullish |
| vs SMA20 | 0.986x | Below |
| vs SMA50 | 0.950x | Below |
| vs SMA200 | 0.863x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $118.25
- **Stop Loss:** $112.43 (4.9% risk)
- **Target:** $129.89 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 163
- **Position Value:** $19,274.75
- **Portfolio %:** 19.27%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-12 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.17 | $2.51 | -20.9% |
| 2025Q2 | $2.75 | $2.95 | +7.3% |
| 2025Q1 | $2.02 | $2.00 | -0.9% |
| 2024Q4 | $2.13 | $2.24 | +5.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*